Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis.

ABSTRACT:

Background

Frequent failures observed in some trials comparing the efficacy and safety of osimertinib plus bevacizumab to osimertinib monotherapy in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) alterations have brought questions.

Objectives

To evaluate the efficacy and safety of these two treatment regimens in advanced NSCLC patients harboring EGFR mutations.

Design

This study is a systematic review and meta-analysis.

Data sources and methods

PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, and VIP databases were extensively searched for relevant randomized controlled trials (RCTs) on 14 May 2023. Two researchers independently screened the literature, assessed quality, and extracted data. The primary o

SUBMITTER: Zhou G 

PROVIDER: S-EPMC10832416 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature